Reuters logo
BRIEF-Innate Pharma acquires anti-c5ar from Novo Nordisk A/S
June 2, 2017 / 9:01 PM / 6 months ago

BRIEF-Innate Pharma acquires anti-c5ar from Novo Nordisk A/S

June 2 (Reuters) - Innate Pharma Sa:

* Innate Pharma acquires anti-c5ar, a first-in-class clinical-stage antibody, from Novo Nordisk A/S

* Innate Pharma SA - ‍terms of transaction provide for a total upfront payment of EUR 40 million​

* Innate Pharma SA- innate pharma intends to start clinical trials with anti-c5ar (iph5401) in oncology in 2018

* Innate Pharma SA- acquisition is part of a transaction in which Novo Nordisk A/S will increase its equity stake in Innate Pharma

* Innate Pharma SA - ‍total upfront payment of eur 40 million, consists of eur 37.2m to be paid in new innate pharma shares and eur 2.8 million in cash​

* Innate Pharma - after issuance of new shares, stake of Novo Nordisk A/S in innate pharma will increase from 10.3% to between 14.6 pct to 15.8 pct

* Innate Pharma SA - ‍novo Nordisk A/S will also be eligible for double digit royalties on net sales​

* Innate Pharma - ‍novo Nordisk A/S will be eligible for eur 370 million in development, regulatory and sales milestone payments​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below